StageZero Life Sciences Ltd: StageZero Life Sciences Announces First Closing of CDN $3.7 Million Private Placement

TORONTO, ON / ACCESSWIRE / July 11, 2019 / StageZero Life Sciences Ltd (TSX: SZLS) ("StageZero" or the "Company") today announced the first closing for $2,665,418 of the $3.708 million private placement financing round as approved by shareholders at the Company's Annual and Special Meeting. StageZero anticipates a final closing by July 19, 2019. The private placement is fully subscribed.

According to the first closing, a total of 42 investors participated for total gross proceeds of $2,665,418. The private placement is structured as units at $0.115 and each unit includes one common share and one half warrant, whereby each full warrant can be exercised for a period of 36 months at a price of $0.185.

"The financing is important in its timing as the company enters a growth phase of commercialization and begins its final validation of Aristotle," says James R Howard-Tripp, Chief Executive Officer of StageZero Life Sciences Ltd. "The funding will provide the company with the necessary finances to support new distribution agreements with telehealth partners and grow existing channels within large healthcare systems and employer groups."

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection (Stage 0) of cancer and multiple disease states through whole blood. Our next generation test, Aristotle, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of Aristotle is currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contact:

James R. Howard-Tripp
Chairman & CEO
[e-mail]
Tel: [phone] Ext. 1

Jerome Cliche
Financial Communication Advisor
[e-mail]
Tel. [phone]

SOURCE: StageZero Life Sciences Ltd

View source version on accesswire.com:
https://www.accesswire.com/551608/StageZero-Life-Sciences-Announces-First-Closing-of-CDN-37-Million-Private-Placement